Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cue Biopharma reports robust clinical data and strategic partnerships

Cue Biopharma's Q4 2022 Earnings Call highlighted strong clinical data, strategic partnerships, and upcoming milestones that position the company for growth and innovation in the biopharmaceutical sector.
While facing challenges in determining optimal registration paths and patient stratification, Cue Biopharma remains focused on leveraging opportunities through partnerships, therapeutic breakthroughs, and financial stability.
With a clear focus on advancing their pipeline, Cue Biopharma aims to drive therapeutic advancements, expand their portfolio, and establish themselves as a key player in oncology treatments.

Cue Biopharma reports strong Q2 performance and eyes transformative 2024

Cue Biopharma's Q2 2023 performance showcased revenue growth, strong cash position, and promising clinical data from trials, underlining the company's commitment to precision immunotherapy in cancer treatment.
The company's strengths in harnessing natural immune signals, achieving significant antitumor activity, and exploring rational combinations position Cue Biopharma for transformative advancements.
Challenges in decision-making, dose determination, and regulatory pathways must be navigated, but opportunities in FDA resolutions, strategic decisions, and milestone achievements abound.
With a focus on data interpretation, partnerships, and transformative therapies, Cue Biopharma is poised for an exciting and impactful 2024 with multiple milestones and growth prospects.

Cue Biopharma reports positive trial outcomes and explores strategic partnerships

Cue Biopharma's Q3 showcased strong clinical progress and financial stability.
The company's Immuno-STAT platform trials displayed promising results.
Challenges include regulatory pathways and trial expansion plans.
Opportunities lie in strategic partnerships and exploring new treatment combinations.

Cue Biopharma reports solid financials and advances in immunotherapy

Cue Biopharma's financials show steady revenue growth and prudent expense management, ensuring operational funding into 2025.
The company's strengths lie in its focused approach to developing immunotherapeutic biologics and positive trial updates in oncology and autoimmune diseases.
Challenges include strategic decision-making on partnerships, trial design, and managing trial outcome expectations based on industry data.
Opportunities exist in strategic partnerships, advancements in oncology programs, and upcoming data presentations offering insights for stakeholders.

Cue Biopharma advances autoimmune programs and partnerships for treatment innovation

Cue Biopharma's focus on autoimmune programs and strategic partnerships reflects a commitment to redefining treatment standards for cancer and autoimmune diseases. Progress with key programs and the Immuno-STAT platform demonstrates potential for targeted therapies with improved efficacy and safety. Overcoming challenges in market conditions and regulatory landscapes while seizing opportunities in program advancements and partnerships will be critical for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, reported today second quarter 2022 financial results. The Company will host a business update call and webcast on Tuesday, August 23, 2022 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.

Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-based Therapies being held July 12–13, 2022.

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will present at the Jefferies Healthcare Conference being held June 8–10, 2022.

Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company's Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic exposure from legacy CAR-T methodologies.

Cue Biopharma: A First Assessment

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, today reported first quarter 2022 financial results. The Company will not host a business update call in conjunction with its financial results press release.

Cue Biopharma Reports First Quarter 2022 Financial Results

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, will provide a clinical update during today's conference call and webcast at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website.

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company's website.

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient's body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021.

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will take part in two fireside chats, the first at the Stifel Healthcare Conference 2021, November 15-17, and the second at the Jefferies London Healthcare Conference, November 16-19. Both conferences will be held virtually.

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for

Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalovirus (CMV) highlighting potential as immunotherapeutics for a variety of chronic infectious diseases Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalovirus (CMV) highlighting potential as immunotherapeutics for a variety of chronic infectious diseases

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today the publication of research titled “ Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells ” in the peer-reviewed Nature journal, Scientific Reports. The article describes Cue Biopharma's IL-2 based CUE-100 series technology platforms, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and Neo-STAT™, being leveraged for the development of first-in-class biologics that enable selective activation of cancer-killing immune T cells within the patient's body.

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT

Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient's body, provided a business and clinical progress update for the second quarter 2021.

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held August 9-10 2021.

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.

News for Cue Biopharma Stock (CUE)